Article says PhotoCure's PCI technology enhances gene therapy

By Lisa Kerner

Erie, Pa., March 28 - PhotoCure and its subsidiary, PCI Biotech, are developing a proprietary technology for site-specific drug delivery and drug enhancement called Photochemical Internalization (PCI).

An article published in the gene therapy journal Molecular Therapy states PCI can be used for enhancing gene therapy in cancer, based on an animal model.

In the model, PCI technology improved a non-functional gene therapy to the point where more than 80% of the animals were cured from their tumors, according to a company news release.

"Achieving safe and efficient gene delivery in the body has been a major limiting factor in the development of gene therapy," president and chief executive officer Kevil Festal said in the release.

"This article demonstrates that with the PCI technology, efficient cancer gene therapy can be achieved without the use of virus gene delivery agents, the side effects of which have severely hampered the progress of gene therapy as a clinical treatment."

PCI Biotech commercializes PhotoCure's proprietary technology for PCI.

PhotoCure, an Oslo, Norway-based pharmaceutical company, develops and sells pharmaceuticals and medical devices based on proprietary photodynamic technologies, targeting the dermatology and oncology markets.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.